LEADER 02375nam 22004693 450 001 9910827045803321 005 20210901203632.0 010 $a1-5231-4979-5 010 $a92-0-122621-7 035 $a(CKB)4100000011994120 035 $a(MiAaPQ)EBC6687105 035 $a(Au-PeEL)EBL6687105 035 $a(NjHacI)994100000011994120 035 $a(EXLCZ)994100000011994120 100 $a20210901d2021 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aProduction and Quality Control of Fluorine-18 Labelled Radiopharmaceuticals 210 1$aVienna :$cIAEA,$d2021. 210 4$dİ2021. 215 $a1 online resource (168 pages) 225 1 $aIAEA TECDOC Series ;$vv.1968 311 $a92-0-122721-3 320 $aIncludes bibliographical references. 330 $aSince their clinical use initiation in the 1970's, Fluorine-18 (F-18) radiopharmaceuticals continue to play an important role in nuclear medicine. It is therefore essential to make available broad information on practical production routes and optimal quality control for F-18 tracers, to achieve the best possible products in high quantity and quality for clinical applications while fulfilling all regulatory requirements. This publication describes the chemical and biological properties of F-18 radiopharmaceuticals. This includes aspects relating to F-18 target production and radiofluorination methods, with focus on the applied techniques. The publication presents a disease oriented approach, describing F-18 radiopharmaceuticals, ranging from the physiological/biological aspects to dedicated radiopharmaceutical development approaches and provides readers with clear guidelines and methods for the production of F-18 radiopharmaceuticals. 410 0$aIAEA TECDOC Series 606 $aRadiopharmaceuticals$xSynthesis$vCongresses 606 $aRadiopharmaceuticals$xTesting$vCongresses 615 0$aRadiopharmaceuticals$xSynthesis 615 0$aRadiopharmaceuticals$xTesting 676 $a616.07575 700 $aIAEA$01594159 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910827045803321 996 $aProduction and Quality Control of Fluorine-18 Labelled Radiopharmaceuticals$93967576 997 $aUNINA